Trials / Completed
CompletedNCT01230125
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 311 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mapracorat | Instill study medication into study eye per dosing instructions for 14 days |
| DRUG | Vehicle | Instill study medication into the study eye per dosing instructions for 14 days |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-08-01
- First posted
- 2010-10-28
- Last updated
- 2020-09-03
- Results posted
- 2020-09-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01230125. Inclusion in this directory is not an endorsement.